STP938

DRUG3 trials

Sponsors

Step Pharma, SAS

Conditions

Essential ThrombocythaemiaLymphoma, B-CellLymphoma, T-CellSolid Tumor

Phase 1

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

RecruitingNCT05463263

Step Pharma, SASLymphoma, B-Cell, Lymphoma, T-Cell

Start: 2022-08-03End: 2026-12-01Target: 180Updated: 2026-06-16

Study of STP938 (Dencatistat) in Advanced Solid Tumours

RecruitingNCT06297525

Step Pharma, SASSolid Tumor

Start: 2024-08-02End: 2027-05-01Target: 70Updated: 2026-06-16

Phase 2

A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

RecruitingNCT06786234

Step Pharma, SASEssential Thrombocythaemia

Start: 2025-06-18End: 2028-09-30Target: 50Updated: 2026-06-16

Related Papers

Abstract CT075: Lack of CTPS2 expression exposes synthetic lethal vulnerability to selective CTPS1 inhibition: A phase 1 dose escalation study of dencatistat (STP938) with safety expansion in biomarker selected cohorts

Cancer Research2026-04-17

Abstract 4560: CTPS1 as a metabolic vulnerability and novel therapeutic target in breast and ovarian cancer

Cancer Research2026-04-03

Abstract IA04: Using GENIE data to drive oncology target identification and drug development

Molecular Cancer Therapeutics2025-10-22

Abstract PR005: Exploiting CTPS1 dependency for the treatment of ovarian cancer

Cancer Research2025-09-19

Abstract 1620: Vulnerability to selective CTPS1 inhibition in cancers lacking CTPS2

Cancer Research2025-04-21

Abstract 6388: Exploiting CTPS1 dependency for the treatment of breast and ovarian cancer

Cancer Research2025-04-21

Abstract LB405: CTP synthase 1 is a synthetic vulnerability in prostate cancer treated with supraphysiological androgen

Cancer Research2024-04-05

A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.

Journal of Clinical Oncology2023-06-01

<scp>MYC</scp>‐induced cytidine metabolism regulates survival and drug resistance via <scp>cGas‐STING</scp> pathway in mantle cell lymphoma

British Journal of Haematology2023-05-2410 citations

CTP Synthase 1 Is a Novel Therapeutic Target in Lymphoma

HemaSphere2023-03-2816 citations